| Literature DB >> 31150426 |
Juliana E Brondani1, Fabio V Comim1, Liziane M Flores2, Lígia Araújo Martini3, Melissa O Premaor1.
Abstract
BACKGROUND: Although intake of fruits and vegetables seemed to have a protective effect on bone metabolism, its effect on fractures remains uncertain.Entities:
Mesh:
Year: 2019 PMID: 31150426 PMCID: PMC6544223 DOI: 10.1371/journal.pone.0217223
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA 2009 flow diagram of the selection of studies included in the review.
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009), Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed.1000097. For more information, visit www.prisma-statement.org.
Characteristics of the cohort studies included in the systematic review.
| Author, year (location) | Subject number | Mean age | Follow-up | Dietary assessment | Dietary assessment validation | Fruits and vegetable intake | Study Quality |
|---|---|---|---|---|---|---|---|
| De Jonge et al., 2017 (Netherlands)[ | 2323(F);1705(M) | 66.0 | 14.8 | FFQ (170 foods) | Yes | Dietary pattern rich in F/V | 8★ |
| Byberg et al., 2015 (Sweden)[ | 34 947 (F); 40 644 (M) | ≥59 | 14.2 | FFQ (96 foods) | Yes | F/V serving | 8★ |
| Fung et al., 2015 (USA)[ | 74 540 (F); 35 451 (M) | ≥50 | 20 | FFQ (130 foods) | Yes | Dietary pattern rich in F/V | 8★ |
| Samieri et al., 2013 (France)[ | 932 (F); 550 (M) | 76 | 8 | FFQ (148 foods); 24h-R | Yes | Dietary pattern rich in F/V | 7★ |
| Benetou et al., 2011 (Europe)[ | 18 584 (F); 10 538 (M) | 64.3 | 8 | FFQ | Yes | F/V serving | 8★ |
| Langsetmo et al., 2011 (Canada)[ | 1849 (F); 891 (M) | 66.6 | 6.7 | FFQ (51 foods e 18 drinks) | Yes | Dietary pattern rich in in F/V | 8★ |
| Kaptoge et al., 2003 (UK)[ | 474 (F); 470 (M) | 74.6 | 2.8 | 7d-FR | Yes | Tertile of F/V | 8★ |
| Tucker et al., 1999 (USA)[ | 716 (F); 448 (M) | 75.2 | 4 | FFQ (126 foods) | Yes | F/V serving | 8★ |
*years
** Newcastle-Ottawa Scale for cohort studies was obtained to assess the selection, comparability and outcome for the cohort study. ★ = 1 point
*** The food-frequency questionnaires were developed and validated within each country of the study (Italy, Netherlands, Greece, Germany, and Sweden)
F = female; M = male
FFQ = food frequency questionnaire; 24h-R = 24-hour food recall; 7d-FR = 7-day food record
F/V = fruit and vegetable
a The patterns were calculated using data reduction technique. It adjusted for total calorie intake (kg/day). It not includes legumes and potatoes.
b The mean size of the fruits and vegetable serving was 101g. It not includes legumes and potatoes.
c The patterns were calculated using the orthogonal rotation procedure. It not includes legumes and potatoes.
d The patterns were calculated using principal component analysis. It adjusted for total calorie intake (kg/day). It includes legumes and potatoes.
e The patterns were calculated using factor analysis. It not includes legumes and potatoes.
Characteristics of randomized clinical trial included in the systematic review.
| Author, year (location) | Subject number | Mean age | Follow-up | Dietary assessment | Intervention | Control group | Evaluated Outcomes | Study Quality |
|---|---|---|---|---|---|---|---|---|
| Macdonald et al., 2008 (UK)[ | 202 (F); IGa n = 101; IGb n = 51; CG n = 47 | 55–65 | 2 years | FFQ (130 foods) | IGa | Received no dietary advice plus placebo capsules | CTx, P1NP BMD | L |
| Ebrahimof et al., 2009 (Iran)[ | 45 (F); IG n = 23; CG n = 22 | 50–60 | 12 weeks | 7 days of 24h-R | 400g F/V day; they received the daily amount of fresh vegetables weighted and packed once a week | No intervention | OC, CTx | H |
| McTiernan et al., 2009 (USA)[ | 48835 (F); IG n = 19541; GC n = 29294 | 50–79 | 8.1 years | FFQ (122 foods) | Intensive behavioral program (18 group section) to increase the servings of F/V to ≥ 5 day | No intervention | Incidence of fractures BMD | H |
| Neville et al., 2014 (UK)[ | 52 (F); 28 (M); IG n = 41; CG n = 39 | 69.9 (F) 73 (M) | 16 weeks | 7 days of 24h-R | ≥ 5 servings F/V day was prescribe, they received fresh fruits and vegetables | ≤ 2 servings F/V day was prescribed, they received fresh fruits and vegetables | OC, CTx | H |
| Gunn et al., 2015 (New Zeland)[ | 141 (F); IGa n = 48; IGb n = 50; CG n = 43 | 50–70 | 12 weeks | 3 days of 24h-R | IGa ≥ 9 servings F/V day was prescribed; IGb | No intervention | CTx, P1NP | H |
*years
** The follow-up time was evaluated from de randomization
***Evaluation of the Randomized Trials Bias Risk according to the Cochrane Collaboration tool. H = High; L = Low
F = female, M = male
FFQ = food frequency questionnaire; 24h-R = 24-hour food recall;
F/V = fruit and vegetable
BMD = bone mineral density; CTx = C-terminal telopeptide; P1NP = pro-peptide aminoterminal procollagen type I, OC = osteocalcin.
a* this group was not taken in consideration in this review and its pooled analysis
Fig 2Forest plot of the hazard ratio and 95% confidence interval of the risk of hip fractures with combined fruit and vegetable intake in men and women in cohort studies.
Grading of Recommendations Assessment, Developing and Evaluation used to assess the systematic review outcomes.
| Pooled hip fracture | Pooled any fracture | Pooled Ctx | |
|---|---|---|---|
| Risk of Bias | 0 ‘not serious’ | 0 ‘not serious’ | - 1 ‘serious’ |
| Inconsistency | 0 ‘not serious’ | 0 ‘not serious’ | 0 ‘not serious’ |
| Indirectness | 0 ‘not serious’ | 0 ‘not serious’ | 0 ‘not serious’ |
| Imprecision | 0 ‘not serious’ | 0 ‘not serious’ | - 1 ‘serious’ |
| Publication bias | 0 ‘undetected’ | 0 ‘undetected’ | 0 ‘undetected’ |
| Large effect | 0 | 0 | 0 |
| Dose response | 0 | 0 | 0 |
| All plausible residual Confounding | + 1 ‘Would reduce a demonstrated effect’ | + 1 ‘Would reduce a demonstrated effect’ | 0 |
| 3 = | 3 = | 2 = |
CTx = C-terminal telopeptide
Fig 3Forest plot of the standard means difference and 95% confidence interval of the C-terminal telopeptide after 3 months combined with fruit and vegetable intake in randomized clinical trials.